| Autor: |
Su, Zhen, Wei, Fusheng, Fesperman, Susan, Wang, Siqing, Dahm, Philipp, Vieweg, Johannes |
| Zdroj: |
Blood; November 2006, Vol. 108 Issue: 11 p3704-3704, 1p |
| Abstrakt: |
The major objective of this study is to develop a novel and broadly applicable immunotherapy platform against cancer and infectious diseases. We hypothesized that human embryonic stem cells (hESC) could serve as a source for generating dendritic cells (DC) with potent immunostimulatory function. One advantage of using hESC-derived DC in clinical settings is the ability to generate virtually unlimited amounts of antigen presenting cells for vaccination. Although hESC-derived DC are not genetically identical to the recipient patient, antigen processing and presentation can be facilitated by matching hESC to recipients that share HLA class I alleles. Another advantage of this technology is that hESC express highly polymorphic HLA class II molecules that serve as major rejection antigens, thereby augmenting the antigen-specific T-cell response in the cancer patient. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
